Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXT-107 Safety and Bioactivity in Diabetic Macular Edema
NCT04697758Phase 2Terminated
- Sponsor
- AsclepiX Therapeutics
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of gersizangitide in diabetic macular edema (DME), sponsored by AsclepiX Therapeutics. Started Dec 2020; status: terminated.
02
Drugs
gersizangitide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04697758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697758.